Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 7OTHER 5OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Sarcopenia 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

Oxaliplatin 10Fluorouracil 6Irinotecan 5Docetaxel 5Capecitabine 5tislelizumab 4S 1 (combination) 4Paclitaxel 4Endoscopic Mucosal Resection 4XELOX 3Levoleucovorin 3Laparoscopy 3Folfox protocol 3sintilimab 2apatinib 2Proton Pump Inhibitors 2Gastroenterostomy 2Gastrectomy 2Clarithromycin 2Chemotherapy, Adjuvant 2Amoxicillin 2vactosertib 1titanium silicide 1pembrolizumab 1lenvatinib 1durvalumab 1bismuth tripotassium dicitrate 1anlotinib 1Trastuzumab 1Tranexamic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Stomach Neoplasms × durvalumab × Clear all
NCT04893252 2022-11-30

Vactosertib and Durvalumab in Gastric Cancer

National Cancer Center, Korea

Phase 2 Unknown
55 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡